Pilot Feasibility Study of Remote Problem Management Plus for Adults Affected by COVID-19 (PM+)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04617262 |
|
Recruitment Status :
Recruiting
First Posted : November 5, 2020
Last Update Posted : July 14, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Depression Anxiety Disorders Psychological Distress | Behavioral: Remote Problem Management Plus | Not Applicable |
Show detailed description
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 100 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Pilot Feasibility Study of Remote Problem Management Plus to Improve Well-being and Functioning of Adults Affected by COVID- |
| Actual Study Start Date : | January 27, 2021 |
| Estimated Primary Completion Date : | September 2021 |
| Estimated Study Completion Date : | December 2021 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Remote Problem Management Plus
Five individual sessions of low-intensity psychological intervention
|
Behavioral: Remote Problem Management Plus
Five sessions of low-intensity, trans-diagnostic psychological intervention including the teaching and practice of the following strategies: stress management, problem solving, behavioral activation, and strengthening social support |
- Psychological Outcomes Profile; Unabbreviated scale title "Psychological Outcomes Profile" [ Time Frame: 1 week post-intervention ]4-item measure of personalized distress and client-generated problems, function and wellbeing; minimum value = 0, maximum value = 20; higher scores mean greater distress
- Patient Health Questionnaire; Unabbreviated scale title "Patient Health Questionnaire" [ Time Frame: 1 week post-intervention ]9-item measure of depression symptoms; minimum value = 0, maximum value = 27; higher scores mean more severe depression symptoms
- Generalized Anxiety Disorder Scale; Unabbreviated scale title "Generalized Anxiety Disorder 7-item Scale" [ Time Frame: 1 week post-intervention ]7-item measure of anxiety symptoms; minimum value = 0 and maximum value = 21; higher scores mean more severe anxiety symptoms
- World Health Organization Disability Assessment Scale 2.0; Unabbreviated scale title "World Health Organization Disability Assessment Scale 2.0" [ Time Frame: 1 week post-intervention ]12-item measure of ability to engage in daily activities and functioning; minimum value = 0, maximum value = 48; higher scores mean worse disability outcomes
- World Health Organization Quality of Life Questionnaire-BREF; Unabbreviated scale title "World Health Organization Quality of Life Questionnaire-BREF" [ Time Frame: 1 week post-intervention ]26-item quality of life assessment of physical health, psychological health, social, relationships and environment; minimum value = 26 and maximum value = 130; higher scores mean better quality of life
- EuroQoL 5-dimension 5-level; Unabbreviated scale title "EuroQoL 5-dimension 5-level" [ Time Frame: 1 week post-intervention ]5-item assessment of dimensions of health status: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; minimum= 5, maximum = 25; higher score mean worse health outcomes
- Pittsburgh Sleep Quality Index; Unabbreviated scale title "Pittsburgh Sleep Quality Index" [ Time Frame: 1 week post-intervention ]19-item measure of sleep quality and disturbance; 19 items combined to form 7 "component" scores, each of which has a range of 0-3 points, 7 component scores are added to yield one global global score; minimum value = 0 and maximum value = 21; higher score means greater difficulty sleeping
- Somatic Symptom Scale-8; Unabbreviated scale title "Somatic Symptom Scale-8" [ Time Frame: 1 week post-intervention ]8-item assessment of the presence and severity of common somatic symptoms; minimum value = 0, maximum value = 32; higher score means more severe somatic symptoms
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- English-speaking
- Help- or treatment-seeking
- Access to a device for conducting sessions via Zoom (e.g., smartphone, tablet, laptop or personal computer)
Exclusion Criteria:
- Acute medical conditions or severe cognitive impairment (e.g., severe intellectual disability or dementia)
- Imminent suicide risk or expressed acute needs/protection risks (e.g., IPV risk)
- Presence of severe mental disorder (e.g., psychotic disorders)
- Hazardous substance use, substance dependency or substance use disorder (assessed using the DAST-10 and AUDIT-C)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04617262
| Contact: Kendall Pfeffer, MEd, MA | 212-229-5727 | pfefk996@newschool.edu | |
| Contact: Adam Brown, PhD | 212-229-5727 | brownad@newschool.edu |
| United States, New York | |
| The New School | Recruiting |
| New York, New York, United States, 10011 | |
| Contact: Kendall Pfeffer, MEd, MA 212-229-5727 pfefk996@newschool.edu | |
| Contact: Adam Brown, PhD 212-229-5727 brownad@newschool.edu | |
| Principal Investigator: | Adam Brown, PhD | The New School | |
| Study Director: | Brandon Kohrt, MD, PhD | George Washington University |
Publications:
| Responsible Party: | The New School |
| ClinicalTrials.gov Identifier: | NCT04617262 |
| Other Study ID Numbers: |
2020-91-PM+ |
| First Posted: | November 5, 2020 Key Record Dates |
| Last Update Posted: | July 14, 2021 |
| Last Verified: | July 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | De-identified individual patient data will be available through NIMH Data Archive after publication of primary results. |
| Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) Analytic Code |
| Time Frame: | Materials will be shared after publication of primary results. |
| Access Criteria: | Contact investigators. |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Anxiety Disorders Mental Disorders |

